Table 2. Clinical data and comparison of single HMPV infections vs coinfections.
| HMPV single (N = 133) | HMPV coinfection (N = 81) | P | OR (IC 95%) | |
|---|---|---|---|---|
| Sex: males | 77 (57.9%) | 48 (59.3%) | 0.844 | 1.036 (0.73–1.470) |
| Age ± SD (months) | 14.37 ± 20.85 | 12.9 ± 11.69 | 0.606 | |
| Fever ≥ 38° | 90 (67.7%) | 58 (71.6%) | 0.545 | 1.125 (0.764–1.655) |
| Maximum Tª (°C) | 38.83 ± 0.62 | 38.84 ± 0.62 | 0.900 | |
| Days of fever | 2.6 ± 1.6 | 2.9 ± 1.7 | 0.381 | |
| SatO2 < 95% | 83 (62.4%) | 57 (70.4%) | 0.235 | 1.255 (0.854–1.845) |
| Days of hypoxia* | 2.6 ± 1.8 | 3,2 ± 2.4 | 0.095 | |
| Days of hospitalization* | 4.2 ± 2.1 | 4.9 ± 2.6 | 0.042 | |
| X-ray | ||||
| Infiltrate | 43 (48.3%) | 24 (46.2%) | 0.804 | |
| Normal | 46 (51.7%) | 28 (53.8%) | ||
| Diagnosis | 0.529 | |||
| Recurrent wheezing/ asthma | 65 (60.7%) | 43 (67.2%) | ||
| Bronchiolitis | 32 (29.9%) | 15 (23.4%) | ||
| Pneumonia | 9 (8.4%) | 4 (6.2%) | ||
| Laryngitis | 1 (0.9%) | 2 (3.1%) | ||
| Prematurity | 20 (15.2%) | 13 (16%) | 0.860 | 1.043 (0.656–1.657) |
| Antibiotic treatment | 34 (25.6%) | 23 (28.4%) | 0.650 | 1.092 (0.750–1.591) |
*Mean ± standard deviation (SD)